# Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )

> **NCT01569295** · PHASE3 · COMPLETED · sponsor: **Gilead Sciences** · enrollment: 416 (actual)

## Conditions studied

- Chronic Lymphocytic Leukemia

## Interventions

- **DRUG:** Idelalisib
- **DRUG:** Rituximab
- **DRUG:** Bendamustine
- **DRUG:** Placebo to match idelalisib

## Key facts

- **NCT ID:** NCT01569295
- **Lead sponsor:** Gilead Sciences
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-06-15
- **Primary completion:** 2019-06-10
- **Final completion:** 2019-06-10
- **Target enrollment:** 416 (ACTUAL)
- **Last updated:** 2020-03-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01569295

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01569295, "Study Evaluating the Efficacy and Safety of Idelalisib in Combination With Bendamustine and Rituximab for Previously Treated Chronic Lymphocytic Leukemia (CLL) (Tugela )". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01569295. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*